Medicare drug discount exemption quietly benefits pharma makers

What it does

This bill exempts certain oral drugs from Medicare Part D's manufacturer discount program. Specifically, it carves out drugs that received FDA approval as new drugs and have been granted a narrow exception by CMS to be reclassified as non-innovator drugs under Medicaid. The effect is that manufacturers of these drugs would no longer be required to provide the discounts that Part D currently mandates.

Why we flagged it

The bill's operative mechanism is a narrow exemption from mandatory manufacturer discounts in Medicare Part D, benefiting pharmaceutical manufacturers of specific oral drugs at the expense of beneficiary cost-sharing.

What the text implies

• The exemption targets drugs that have received a 'narrow exception' reclassification under Medicaid — a CMS determination that is not defined in this bill and may be opaque to public scrutiny. The criteria for such exceptions are not stated here, creating uncertainty about which drugs qualify.
• The bill does not specify how many drugs currently hold or may obtain such narrow exceptions, making the fiscal impact on Medicare and beneficiary costs difficult to estimate.
• By exempting drugs from Part D discounts while they remain subject to Medicaid rebates, the bill creates a two-tier pricing structure that may incentivize manufacturers to seek narrow-exception status for high-value oral drugs.
• The exemption applies only to 'orally administered' drugs, suggesting a deliberate carve-out for a specific drug class or set of manufacturers — the rationale for this limitation is not stated in the bill.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries lose the benefit of mandatory manufacturer discounts on a class of oral drugs, resulting in higher out-of-pocket costs or higher Part D premiums. The exemption flows directly to manufacturers, who retain full pricing discretion on these drugs.

Who stands to gain

• pharmaceutical manufacturers of orally administered drugs with narrow-exception Medicaid reclassific
• specialty pharmaceutical companies

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Medicare Part D, Medicaid drug rebate program, FDA (Federal Food, Drug, and Cosmetic Act, section 505), Social Security Act, section 1860D–14C(g)(2)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Mar 6, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 6, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $188,894 in lobbying spend. A filing names 27 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Andrew Garbarino, the sponsor, reported $1,954,500 in PAC receipts in the 2026 cycle.

• The Ai Policy Network Inc. — $188,894 on 1 filing

Lobbying Disclosure Act filings through Jul 15, 2026. A filing shows who paid to lobby on a bill it names, not what changed.